PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) CEO Stuart Walter Peltz sold 407 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $26.83, for a total value of $10,919.81. Following the sale, the chief executive officer now directly owns 38,239 shares in the company, valued at approximately $1,025,952.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Stuart Walter Peltz also recently made the following trade(s):
- On Thursday, April 14th, Stuart Walter Peltz sold 82 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.28, for a total transaction of $3,712.96.
Shares of PTCT stock traded down $0.29 during trading hours on Thursday, reaching $27.85. 500,948 shares of the company traded hands, compared to its average volume of 677,397. PTC Therapeutics, Inc. has a 12-month low of $26.76 and a 12-month high of $45.80. The company has a quick ratio of 1.59, a current ratio of 1.62 and a debt-to-equity ratio of 679.17. The firm has a 50-day moving average price of $35.77 and a 200 day moving average price of $37.62.
Several brokerages have commented on PTCT. JPMorgan Chase & Co. upped their target price on shares of PTC Therapeutics from $70.00 to $76.00 and gave the company an “overweight” rating in a research note on Wednesday, February 23rd. Barclays decreased their price target on shares of PTC Therapeutics from $40.00 to $39.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $63.00 price target (down previously from $64.00) on shares of PTC Therapeutics in a research report on Friday, April 1st. StockNews.com started coverage on shares of PTC Therapeutics in a research note on Thursday, March 31st. They set a “hold” rating for the company. Finally, Zacks Investment Research downgraded shares of PTC Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, PTC Therapeutics has a consensus rating of “Hold” and an average price target of $50.22.
A number of institutional investors have recently made changes to their positions in PTCT. Charles Schwab Investment Management Inc. raised its stake in PTC Therapeutics by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 499,179 shares of the biopharmaceutical company’s stock valued at $19,883,000 after buying an additional 10,569 shares during the last quarter. Citigroup Inc. lifted its stake in PTC Therapeutics by 75.2% in the 4th quarter. Citigroup Inc. now owns 132,868 shares of the biopharmaceutical company’s stock valued at $5,292,000 after buying an additional 57,012 shares in the last quarter. Camber Capital Management LP purchased a new position in shares of PTC Therapeutics in the 3rd quarter worth $27,908,000. American Century Companies Inc. purchased a new position in shares of PTC Therapeutics in the 3rd quarter worth $490,000. Finally, Jefferies Group LLC purchased a new position in shares of PTC Therapeutics in the 3rd quarter worth $469,000.
PTC Therapeutics Company Profile (Get Rating)
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.
- Get a free copy of the StockNews.com research report on PTC Therapeutics (PTCT)
- The Institutions Are Rotating Into Olli’s Bargain Outlet
- Would Netflix acquiring Roku be a positive for the stock?
- Microcap Oil-Dri Corporation Is A Buy For Income Investors
- Inflation, An Economic Winter Is Approaching
- Now’s The Time To Buy MongoDB (NASDAQ: MDB)
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.